Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02658084 · ClinicalTrials.gov registry record · Phase 1
Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer
A Phase 1 study, sponsored by University of Miami.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02658084 is a Phase 1 study that was terminated before completion, run by University of Miami. The registered enrollment target is 2 participants.
The verdict
NCT02658084, a Phase 1 study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The study proposes to evaluate the safety and efficacy of the combination of trastuzumab emtansine (T-DM1) and vinorelbine in HER2+ metastatic breast cancer patients.
Interventions
- DRUG Vinorelbine
- DRUG Trastuzumab Emtansine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-04-12 |
| Est. Completion | 2018-10-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02658084
The ClinicalTrials.gov registry entry for NCT02658084 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vinorelbine is the first listed.
NCT02658084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02658084 about?
NCT02658084 is a clinical study titled "Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer". The study proposes to evaluate the safety and efficacy of the combination of trastuzumab emtansine (T-DM1) and vinorelbine in HER2+ metastatic breast cancer patients.
What is the current status of trial NCT02658084?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2017-04-12. Estimated completion is 2018-10-11.
What interventions are being tested in trial NCT02658084?
The interventions under investigation include: Vinorelbine (DRUG), Trastuzumab Emtansine (DRUG).
Who is sponsoring clinical trial NCT02658084?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.